When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
ARQL - Ovid Therapeutics: Multiple Ways To Win In This Beaten-Down Biotech
ArQule Inc.
Ovid Therapeutics (OVID) has certainly been a poor performer, with shares having fallen by 87% since its IPO priced at $15 in 2017. While the stock initially produced a 75% run up gain since my initial article, it's fallen by more than 80% since my November 2017 update piece.
The company's Q1 update caught my attention, given that data from the phase 2 STARS study in Angelman syndrome was selected as one of three programs featured at the 2019 American Academy of Neurology ((AAN)) Top Science Press Conference and that readout for phase